Activation of marrow infiltrating lymphocytes in hypoxic alternating with normoxic conditions

Patent metadata

Field	Value
Publication number	US-10406178-B2
Application number	US-201715606766-A
Country	US
Kind code	B2
Filing date	May 26, 2017
Priority date	Sep 4, 2014
Publication date	Sep 10, 2019
Grant date	Sep 10, 2019

Abstract

In some aspects, the invention relates to compositions comprising marrow infiltrating lymphocytes (“MILs”). The MILs may be activated MILs. In some aspects, the invention relates to methods for activating MILs, comprising incubating MILs in an environment comprising less than 21% oxygen. In some aspects, the invention relates to methods for treating cancer in a subject, comprising administering to the subject a composition comprising activated MILs.

First claim

What is claimed:

1. A method for treating a subject having cancer with therapeutic activated marrow infiltrating lymphocytes, the method comprising the steps of:
(a) culturing a bone marrow sample obtained from the subject having cancer with an anti-CD3 antibody and an anti-CD28 antibody in a hypoxic environment of about 1% to about 3% oxygen to produce hypoxic-activated marrow infiltrating lymphocytes;
(b) culturing the hypoxic-activated marrow infiltrating lymphocytes in a normoxic environment in the presence of IL-2 to produce the therapeutic activated marrow infiltrating lymphocytes; and
(c) administering the therapeutic activated marrow infiltrating lymphocytes to the subject having cancer.

2. The method of claim 1 , wherein the bone marrow sample is cultured in the hypoxic environment for about 24 hours.

3. The method of claim 1 , wherein the bone marrow sample is cultured in the hypoxic environment for about 2 days.

4. The method of claim 1 , wherein the bone marrow sample is cultured in the hypoxic environment for about 3 days.

5. The method of claim 1 , wherein the bone marrow sample is cultured in the hypoxic environment for about 2 to about 5 days.

6. The method of claim 1 , wherein the hypoxic environment is about 1% to about 2% oxygen.

7. The method of claim 1 , wherein the hypoxic-activated marrow infiltrating lymphocytes are cultured in the normoxic environment for about 2 to about 12 days.

8. The method of claim 1 , wherein the hypoxic-activated marrow infiltrating lymphocytes are cultured in the normoxic environment for about 6 days.

9. The method of claim 1 , wherein the hypoxic-activated marrow infiltrating lymphocytes are cultured in the normoxic environment for about 9 days.

10. The method of claim 1 , further comprising the step of removing a bone marrow sample from a subject having cancer prior to step (a).

11. The method of claim 1 , wherein the anti-CD3 antibody and the anti-CD28 antibody are bound on a bead.

12. The method of claim 1 , wherein the cancer is a hematological cancer.

13. The method of claim 1 , wherein the cancer is a solid tumor.

14. The method of claim 1 , wherein the cancer is lung cancer or breast cancer.

15. A method for treating a subject having cancer with therapeutic activated marrow infiltrating lymphocytes, the method comprising the steps of:
(a) culturing a bone marrow sample obtained from the subject having multiple myeloma with anti-CD3/anti-CD28 beads in a hypoxic environment of about 1% to about 2% oxygen for about 2 to about 5 days to produce hypoxic-activated marrow infiltrating lymphocytes;
(b) culturing the hypoxic-activated marrow infiltrating lymphocytes in a normoxic environment of about 21% oxygen for about 2 to about 12 days in the presence of IL-2 to produce the therapeutic activated marrow infiltrating lymphocytes; and
(c) administering the therapeutic activated marrow infiltrating lymphocytes to the subject having cancer.

16. The method of claim 15 , wherein the bone marrow is cultured for about 3 days in the hypoxic environment.

17. The method of claim 15 , wherein the hypoxic-activated marrow infiltrating lymphocytes are cultured for about 6 days in the normoxic environment.

18. The method of claim 15 , wherein the hypoxic-activated marrow infiltrating lymphocytes are cultured for about 9 days in the normoxic environment.

19. The method of claim 15 , wherein the cancer is a hematological cancer.

20. The method of claim 15 , wherein the cancer is lung cancer or breast cancer.

Assignees

• Univ Johns Hopkins

Inventors

• Borrello Ivan M
• Noonan Kimberly A

Classifications

• A61P35/00 Primary

  Antineoplastic agents · CPC title

• A61K2035/124

  the cells being hematopoietic, bone marrow derived or blood cells · CPC title

• C12N5/0669

  Bone marrow stromal cells; Whole bone marrow (isolated stem cells from bone marrow C12N5/0647, C12N5/0663) · CPC title

• C12N2501/2302

  Interleukin-2 (IL-2) · CPC title

• C12N2501/998

  Proteins not provided for elsewhere · CPC title